Bavituximab
Based on 2 publication(s) in Google Scholar
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.00%
- CAS 番号: 648904-28-3
- 分子量:145.336 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Bavituximab
More
生物活性
Human IgG1 kappa
Human
Phosphatidylserine
Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1].
Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1].
Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2]
-
Dosage:100 μg/mouse (Bavituximab/β2GP1)
-
Administration:Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)
-
Result:Traced phosphatidylserine exposure in vivo in mice with tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 648904-28-3
-
性状 Liquid
-
分子量 145.336 kDa
-
Color Colorless to light yellow
-
SMILES
[Bavituximab]
-
別名
Anti-Human Phosphatidylserine Recombinant Antibody; PGN-401; CH3G4
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells. [Abstract]2026 May 15. PMID: 42141174 -
Cell Rep Med
Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer. [Abstract]2025 Dec 18:102529. PMID: 41418775
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. [Content Brief]
[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Bavituximab 関連分類
HY-P99279 関連分類
Powered by Bioz